The GHP Investment Advisors Inc. invests in Johnson & Johnson (JNJ) Shares

The GHP Investment Advisors Inc. invests in Johnson & Johnson (JNJ) Shares

GHP Investment Advisors Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the second quarter, Holdings Channel reports. The fund owned 30,314 shares of the company’s stock after buying an additional 109 shares during the period. Johnson & Johnson makes up approximately 0.8% of GHP Investment Advisors Inc.’s holdings, making the stock its 23rd largest position. GHP Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $3,677,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in JNJ. IMS Capital Management raised its stake in shares of Johnson & Johnson by 8.1% in the first quarter. IMS Capital Management now owns 11,096 shares of the company’s stock valued at $1,201,000 after buying an additional 835 shares during the last quarter. Delta Asset Management LLC TN raised its stake in shares of Johnson & Johnson by 3.0% in the first quarter. Delta Asset Management LLC TN now owns 23,831 shares of the company’s stock valued at $2,578,000 after buying an additional 695 shares during the last quarter. Duncker Streett & Co. Inc. raised its stake in shares of Johnson & Johnson by 0.3% in the first quarter. Duncker Streett & Co. Inc. now owns 31,359 shares of the company’s stock valued at $3,393,000 after buying an additional 90 shares during the last quarter. Douglas Lane & Associates LLC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $9,269,000. Finally, Quantitative Systematic Strategies LLC raised its stake in shares of Johnson & Johnson by 304.0% in the first quarter. Quantitative Systematic Strategies LLC now owns 17,664 shares of the company’s stock valued at $1,925,000 after buying an additional 13,292 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded down 0.32% on Friday, hitting $115.33. The stock had a trading volume of 8,813,324 shares. The firm has a market cap of $315.53 billion, a price-to-earnings ratio of 20.24 and a beta of 0.62. The company’s 50 day moving average price is $117.51 and its 200 day moving average price is $117.79. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the consensus estimate of $1.66 by $0.02. The firm earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a return on equity of 25.36% and a net margin of 22.03%. Johnson & Johnson’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.49 EPS. Analysts expect that Johnson & Johnson will post $6.72 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 2.77%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. Johnson & Johnson’s dividend payout ratio is 56.64%.

Several brokerages have issued reports on JNJ. Argus reiterated a “buy” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Friday, October 21st. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. BMO Capital Markets restated an “outperform” rating and issued a $132.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 20th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 11th. Finally, Jefferies Group increased their price target on Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a research report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $120.98.

In related news, Director Charles Prince acquired 875 shares of Johnson & Johnson stock in a transaction dated Friday, October 21st. The stock was purchased at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the purchase, the director now directly owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.11% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment